Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a prospective, single-arm phase II study

Name: Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a prospective, single-arm phase II study
Creator: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University
Published: 2025-10-24T10:05:04+08:00

integrated proteome resources2026-02-07 收录

原发灶不明癌症治疗

肿瘤免疫联合疗法

数据链接：

https://www.iprox.cn/page/project.html?id=IPX0013911000 数据链接链接失效反馈

官方服务：

资源简介：

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a prospective, single-arm phase II study

提供机构：

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University

创建时间：

2025-10-24